Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
| dc.citation.title | ecancermedicalscience | es |
| dc.citation.volume | 11 | es |
| dc.creator | Perroud, Herman A | |
| dc.creator | Scharovsky, O. Graciela | |
| dc.creator | Rozados, Viviana R. | |
| dc.creator | Alasino, Carlos María | |
| dc.date.accessioned | 2018-07-02T15:36:08Z | |
| dc.date.available | 2018-07-02T15:36:08Z | |
| dc.date.issued | 2017-02-28 | |
| dc.description | Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease. | es |
| dc.description.fil | Fil: Perroud, Herman A. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina | es |
| dc.description.fil | Fil: Scharovsky, Graciela Olga. Universidad Nacional de Rosario. Consejo de Investigaciones UNR, Facultad de Ciencias Médicas; Argentina | es |
| dc.description.fil | Fil: Rozados, Viviana R. Institute of Experimental Genetics. School of Medical Sciences. National University of Rosario; Rosario; Argentina | es |
| dc.description.fil | Fil: Alasino, Carlos María. Institute of Oncology of Rosario; Argentina | es |
| dc.description.sponsorship | Fundación Roemmers | es |
| dc.description.sponsorship | Ministerio de Ciencia, Tecnología e Innovación de Santa Fe, Argentina. | es |
| dc.format | application/pdf | |
| dc.format.extent | 1-10 | es |
| dc.identifier.issn | 1754-6605 | es |
| dc.identifier.uri | http://hdl.handle.net/2133/11512 | |
| dc.language.iso | eng | es |
| dc.publisher | Cancer Intelligence | es |
| dc.relation.publisherversion | https://doi.org/10.3332/ecancer.2017.723 | es |
| dc.rights | openAccess | es |
| dc.rights.holder | Perroud et al.; licensee PubMed Central | es |
| dc.rights.holder | © the authors; licensee ecancermedicalscience | es |
| dc.rights.text | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | es |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/ar/ | * |
| dc.subject | ovarian cancer | es |
| dc.subject | metronomic chemotherapy | es |
| dc.subject | cyclophosphamide | es |
| dc.title | Clinical response in patients with ovarian cancer treated with metronomic chemotherapy | es |
| dc.type | article | |
| dc.type | artículo | |
| dc.type | publishedVersion | |
| dc.type.collection | articulo | |
| dc.type.version | publishedVersion | es |